S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:APRE

Aprea Therapeutics (APRE) Stock Price, News & Analysis

$8.00
-0.46 (-5.44%)
(As of 03/1/2024 ET)
Today's Range
$7.72
$8.85
50-Day Range
$3.65
$8.46
52-Week Range
$2.78
$8.85
Volume
28,900 shs
Average Volume
14,935 shs
Market Capitalization
$29.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Aprea Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.3% Upside
$14.50 Price Target
Short Interest
Healthy
2.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.29mentions of Aprea Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.07) to ($1.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

285th out of 947 stocks

Biotechnology Industry

4th out of 24 stocks


APRE stock logo

About Aprea Therapeutics Stock (NASDAQ:APRE)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

APRE Stock Price History

APRE Stock News Headlines

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update
Aprea Therapeutics Inc (APRE)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Aprea Therapeutics Inc.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Aprea Therapeutics GAAP EPS of -$0.86
Aprea Therapeutics (APRE) Gets a Buy from Maxim Group
See More Headlines
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/03/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:APRE
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.50
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+81.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-112,660,000.00
Pretax Margin
-2,330.88%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.66 per share

Miscellaneous

Free Float
2,956,000
Market Cap
$29.92 million
Optionable
No Data
Beta
1.05
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Oren Gilad Ph.D. (Age 55)
    Co-Founder, CEO, President and Director
    Comp: $520.84k
  • Mr. John P. Hamill CPA (Age 60)
    Senior VP, CFO, Principal Accounting Officer & Secretary
  • Dr. Dansu Li Ph.D.
    Head of Technology
  • Dr. Lars B. Abrahmsen Ph.D. (Age 67)
    Senior VP & Chief Scientific Officer
  • Dr. Michel Afargan Ph.D.
    Head of Pharmacology Development
  • Mr. Ze'ev Weiss B.Sc. (Age 62)
    C.P.A., Chief Business Advisor
  • Ms. Andrea Epstein
    Controller














APRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aprea Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APRE shares.
View APRE analyst ratings
or view top-rated stocks.

What is Aprea Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 12 month target prices for Aprea Therapeutics' shares. Their APRE share price targets range from $9.00 to $20.00. On average, they anticipate the company's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 81.3% from the stock's current price.
View analysts price targets for APRE
or view top-rated stocks among Wall Street analysts.

How have APRE shares performed in 2024?

Aprea Therapeutics' stock was trading at $4.70 on January 1st, 2024. Since then, APRE stock has increased by 70.2% and is now trading at $8.00.
View the best growth stocks for 2024 here
.

Are investors shorting Aprea Therapeutics?

Aprea Therapeutics saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 79,400 shares, a decline of 20.5% from the January 31st total of 99,900 shares. Based on an average daily volume of 14,100 shares, the short-interest ratio is presently 5.6 days. Approximately 2.5% of the company's shares are sold short.
View Aprea Therapeutics' Short Interest
.

When is Aprea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our APRE earnings forecast
.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) announced its quarterly earnings results on Monday, November, 8th. The company reported ($9.00) EPS for the quarter, meeting the consensus estimate of ($9.00).

When did Aprea Therapeutics' stock split?

Aprea Therapeutics shares reverse split on the morning of Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

When did Aprea Therapeutics IPO?

(APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO.

Who are Aprea Therapeutics' major shareholders?

Aprea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Royal Bank of Canada (1.18%), Vanguard Group Inc. (0.93%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar, Gregory Alan Korbel and Lars B Abrahmsen.
View institutional ownership trends
.

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APRE) was last updated on 3/3/2024 by MarketBeat.com Staff